Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms

Leukemia. 2023 Sep;37(9):1912-1914. doi: 10.1038/s41375-023-01981-2. Epub 2023 Jul 31.

Lauren Shih¹, Megan Othus², Kelda Schonhoff¹, Carole Shaw³, Jacob Appelbaum¹, Anna B Halpern^{1

3}, Pamela S Becker^{1

4}, Roland B Walter^{1

3

5

6}, Elihu Estey^{1

3}, Mary-Elizabeth Percival^{7

8}

¹ Department of Medicine, University of Washington, Seattle, WA, USA.
² Public Health Sciences Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
³ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA.
⁴ Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
⁵ Department of Laboratory Medicine & Pathology, University of Washington, Seattle, WA, USA.
⁶ Department of Epidemiology, University of Washington, Seattle, WA, USA.
⁷ Department of Medicine, University of Washington, Seattle, WA, USA. mperciva@uw.edu.
⁸ Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. mperciva@uw.edu.

No abstract available

Publication types